Howard Hochster, MD
Medical Oncology · New Haven, CTNPI 1538160668
Payments from drug & device makers
Across 195 payments — averaging $14,529 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1.5M
- AstraZeneca$362K
- Daiichi Sankyo Inc.$279K
- Bayer$238K
- Genentech, Inc.$110K
- AbbVie$79K
- plus $223K from 17 others
Across 3 payments — averaging $638.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$1K
- Genentech, Inc.$660
- AbbVie$110
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 4 | $1,541,274 |
| AstraZeneca | 24 | $361,955 |
| Daiichi Sankyo Inc. | 19 | $279,253 |
| Bayer | 14 | $238,080 |
| Genentech, Inc. | 19 | $110,132 |
| AbbVie | 9 | $79,429 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $51,629 |
| Macrogenics, Inc. | 17 | $38,946 |
| Mirati Therapeutics, Inc. | 3 | $38,275 |
| Merck | 16 | $13,093 |
| Novartis | 1 | $12,345 |
| Regeneron | 15 | $11,981 |
| Taiho Oncology, Inc. | 4 | $11,160 |
| GSK | 5 | $10,813 |
| Genentech USA, Inc. | 12 | $9,547 |
| Tempus AI, Inc | 4 | $6,940 |
| Exelixis Inc. | 7 | $6,121 |
| Pfizer | 3 | $4,700 |
| Eisai Inc. | 1 | $2,280 |
| Beigene USA, Inc. | 1 | $2,250 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,845 |
| Roche Products Limited | 1 | $990 |
| Astrazeneca UK Limited | 1 | $135 |
How this compares
$2,833,173 in reported general payments places this provider in the 85th percentile of 79 medical oncology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in New Haven
- Lajos PusztaiNew Haven$23.5M
- Sarah GoldbergNew Haven$17.7M
- Harriet KlugerNew Haven$17.7M
- Daniel PetrylakNew Haven$10M
- Ian KropNew Haven$7.5M
- Anne ChiangNew Haven$5.8M
- Noffar BarNew Haven$5.4M
- Scott GettingerNew Haven$5.1M
- Jill LacyNew Haven$3.5M
- Aarti BhatiaNew Haven$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.